Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Amgen

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

    Approximately 38.4 million people in the US are affected by diabetes

    - PMLiVE

    Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

    Almost one million new cases of gastric cancer are diagnosed globally every year

    - PMLiVE

    Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target

    The companies will aim to discover and develop new therapeutics for the group of disorders

    - PMLiVE

    Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition

    The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD

    - PMLiVE

    NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study

    The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate

    - PMLiVE

    Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease

    Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year

    - PMLiVE

    Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

    Immunoglobulin G4-related disease affects approximately 20,000 people in the US

    - PMLiVE

    Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

    Cardiovascular diseases result in an estimated 17.9 million global deaths each year

    - PMLiVE

    Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

    Regulatory submissions are expected to be complete in the first half of this year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links